1534 ET - Eli Lilly's weight-loss pill slightly missed the company's efficacy expectations, but shares slid more than they should've, say UBS analysts. The pill led to 12.4% weight loss, which suggests it's still a viable drug. Consumers who want an oral GPL-1 drug may be willing to sacrifice some efficacy to avoid needles. The pill version will also cater to those looking to buy in cash, who value convenience over maximum efficacy, the analysts say. But the lower efficacy could lead Eli Lilly to offer the pill at a discount, which would hurt its potential boost to the company's earnings. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
August 08, 2025 15:34 ET (19:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。